[1]禚月 鲍霞 庄贺 石金虎.新生儿持续性肺动脉高压病理机制及治疗的研究进展[J].心血管病学进展,2024,(12):1094.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.009]
　ZHUO Yue,BAO Xia,ZHUANG He,et al.Research Progress on Pathological Mechanism and Treatment of?ersistent Pulmonary Hypertension of The Newborn[J].Advances in Cardiovascular Diseases,2024,(12):1094.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.009]
点击复制

新生儿持续性肺动脉高压病理机制及治疗的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年12期
页码:
1094
栏目:
综述
出版日期:
2024-12-25

文章信息/Info

Title:
Research Progress on Pathological Mechanism and Treatment of?ersistent Pulmonary Hypertension of The Newborn
作者:
禚月1 鲍霞 1 庄贺 1 石金虎 2
(1.山东中医药大学康复医学院,山东 济南 250355;2.山东大学第二医院心血管内科,山东 济南 250033)
Author(s):
ZHUO Yue1; BAO Xia1; ZHUANG He1; SHI Jinhu2?/html>
(1.Faculty of Rehabilitation Medicine,Shandong University of Traditional Chinese Medicine,Jinan 250355,Shandong,China;2.Department of Cardiology,Second Hospital of Shandong University,Jinan 250033 ,Shandong,China)
关键词:
新生儿持续性肺动脉高压; 病理机制; 药物治疗; 吸入一氧化氮
Keywords:
Persistent pulmonary hypertension of the newborn; Pathological mechanism; Drug treatment; Inhaled nitric oxide
DOI:
10.16806/j.cnki.issn.1004-3934.2024.12.009
摘要:
新生儿持续性肺动脉高压是导致新生存活儿死亡的重要原因之一，是一类恶性进行性肺血管疾病，病情持续进展引发患儿呼吸受限、低氧血症，最终导致右心衰竭严重威胁患儿的生命。而存活的患儿也常留有其他系统的后遗症，长期影响其生活质量。现就新生儿持续性肺动脉高压的病理机制及治疗进展展开综述，以期为相关研究及临床诊断和治疗提供参考。
Abstract:
Persistent pulmonary hypertension in newborns is one of the important causes of death in newborn surviving infants,and it is a type of malignant progressive pulmonary vascular disease,which leads to respiratory restriction,hypoxemia,and eventually right heart failure,which seriously threatens the lives of children. Surviving children often have sequelae of other systems,which affect their quality of life for a long time. This article reviews the pathological mechanism and treatment progress of neonatal persistent pulmonary hypertension,in order to provide reference for related research,clinical diagnosis and treatment

参考文献/References:

[1].Qasim A,Jain SK. Milrinone use in persistent pulmonary hypertension of the newborn[J]. Neoreviews,2020,21(3):e165-e178.
[2].Mandell E,Kinsella JP,Abman SH. Persistent pulmonary hypertension of the newborn[J]. Pediatr Pulmonol,2021,56(3):661-669.
[3].Jain A,McNamara PJ. Persistent pulmonary hypertension of the newborn:advances in diagnosis and treatment[J]. Semin Fetal Neonatal Med,2015,20(4):262-271.
[4].Singh Y,Tissot C. Echocardiographic evaluation of transitional circulation for the neonatologists[J]. Front Pediatr,2018,6:140.
[5].Abman SH,Hansmann G,Archer SL,et al. Pediatric pulmonary hypertension:guidelines from the American Heart Association and American Thoracic Society[J]. Circulation,2015,132(21):2037-2099.
[6].Habib S,Saini J,Amendoeira S,et al. Hemodynamic instability in hypoxic ischemic encephalopathy:more than just brain injury—Understanding physiology,assessment,and management[J]. Neonatal Netw,2020,39(3):129-136.
[7].刘学丹,周浩泉,李晓春. 新生儿持续肺动脉高压发病的相关危险因素分析[J]. 临床肺科杂志,2020,25(10):1511-1514.
[8].王六超,农绍汉.新生儿持续肺动脉高压的诊治进展[J].吉林医学,2021,42(1):207-210.
[9].Rajagopal S,Yu YA. The pathobiology of pulmonary arterial hypertension[J]. Cardiol Clin,2022,40(1):1-12.
[10].曾康,黄阿娟,郑曼利,等. 早产儿和足月儿持续性肺动脉高压的危险因素比较[J]. 岭南心血管病杂志,2022,28(4):328-333.
[11].Martinho S,Adao R,Leite-Moreira AF,et al. Persistent pulmonary hypertension of the newborn:pathophysiological mechanisms and novel therapeutic approaches[J]. Front Pediatr,2020,8:342.
[12].Singh Y,Lakshminrusimha S. Pathophysiology and management of persistent pulmonary hypertension of the newborn[J]. Clin Perinatol,2021,48(3):595-618.
[13].张培林. 新生儿低氧性呼吸衰竭和持续肺动脉高压治疗进展研究[J]. 中外医疗,2023,42(20):194-198.
[14].Bajolle F,Malekzadeh-Milani S,Lévy M,et al. Multifactorial origin of pulmonary hypertension in a child with congenital heart disease,Down syndrome,and BMPR-2 mutation[J].Pulm Circ,2021,11(3):20458940211027433.
[15].李强强,顾虹. 中国儿童肺动脉高压诊治现状[J]. 心血管病学进展,2024,45(1):7-10.
[16].Kerstjens-Frederikse WS,Bongers EM,Roofthooft MT,et al. TBX4 mutations (small patella syndrome) are associated with childhood-onset pulmonary arterial hypertension[J]. J Med Genet,2013,50(8):500-506.
[17].Maddaloni C,Ronci S,de Rose DU,et al. Neonatal persistent pulmonary hypertension related to a novel TBX4 mutation:case report and review of the literature[J]. Ital J Pediatr,2024,50(1):41.
[18].Zhang X,Zhang C,Li Q,et al. TGF-β receptor mutations and clinical prognosis in Chinese pediatric patients with idiopathic/hereditary pulmonary arterial hypertension[J]. Pulm Circ,2022,12(2):e12076.
[19].苏馨,杨银凤,王丹,等. 袋鼠式护理模式配合婴儿抚触在新生儿窒息复苏中的应用效果[J]. 中国急救复苏与灾害医学杂志,2021,16(12):1415-1417.
[20].王巧红,张新春,白亚飞. 新生儿肺动脉高压的临床症状与护理观察[J].贵州医药,2020,44(12):2006-2007.
[21].Ruopp NF,Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension:a review[J]. JAMA,2022,327(14):1379-1391.
[22].段佳佳,邢景月,王举,等. 一氧化氮吸入治疗新生儿持续肺动脉高压疗效及预后影响因素分析[J]. 中华新生儿科杂志,2021,36(2):48-52.
[23].Zhao Y,Liang L,Liu G,et al. Asphyxia and neonatal respiratory distress syndrome are independent predictors of the nonresponse to inhaled nitric oxide in the newborns with PPHN[J]. Front Pediatr,2021,9:665830.
[24].El-Khazragy N,El Barbary M,Fouad H,et al. Association between genetic variations in carbamoyl-phosphate synthetase gene and persistent neonatal pulmonary hypertension[J]. Eur J Pediatr,2021,180(9):2831-2838.
[25].González A,Bancalari A,Osorio W,et al. Correction:Early use of combined exogenous surfactant and inhaled nitric oxide reduces treatment failure in persistent pulmonary hypertension of the newborn:a randomized controlled trial[J]. J Perinatol,2021,41(1):32-38.
[26].Mohamed WA,Ismail M. A randomized,double-blind,placebo-controlled,prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn[J]. J Perinatol,2012,32(8):608-613.
[27].Zijlstra WMH,Douwes JM,Rosenzweig EB,et al. Survival differences in pediatric pulmonary arterial hypertension:clues to a better understanding of outcome and optimal treatment strategies[J]. J Am Coll Cardiol,2014,63(20):2159-2169.
[28].Gavotto A,T homas F,W erner O,et al. Use of treprostinil in pediatric pulmonary hypertension:case reports and review of the literature[J]. J Cardiovasc Pharmacol,2020,76(1):23-31.
[29].郑碧娟. 米力农联合酚妥拉明对新生儿肺动脉持续高压患儿动脉血气及血清炎症指标的影响[J]. 淮海医药,2023,41(4):407-409.
[30].龚铭丽,张居琪,李文慧,等. 西地那非治疗新生儿持续性肺动脉高压有效性和安全性分析[J]. 中国临床药理学杂志,2023,39(20):3005-3008.
[31].Namachivayam P,Theilen U,Butt WW,et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children[J]. Am J Respir Crit Care Med,2006,174(9):1042-1047.
[32].Deshpande S,Suryawanshi P,Ahya K,et al. Surfactant therapy for early onset pneumonia in late preterm and term neonates needing mechanical ventilation[J]. J Clin Diagn Res,2017,11(8):SC09-SC12.
[33].Weir EK,Archer SL. The mechanism of acute hypoxic pulmonary vasoconstriction:the tale of two channels[J]. FASEB J,1995,9(2):183-189.
[34].Chandrasekharan P,Lakshminrusimha S. Oxygen therapy in preterm infants with pulmonary hypertension[J]. Semin Fetal Neonatal Med.2020,25(2):101070.
[35].Steinhorn RH,Lakshminrusimha S. Oxygen and pulmonary vasodilation:The role of oxidative and nitrosative stress[J]. Semin Fetal Neonatal Med,2020,25(2):101083.
[36].Doymaz S,Zinger M,Sweberg T. Risk factors associated with intracranial hemorrhage in neonates with persistent pulmonary hypertension on ECMO[J]. J Intensive Care,2015,3(1):6.
[37].陈玉兰,杨秀芳,陈简,等. 体外膜肺氧合技术在持续肺动脉高压新生儿救治中的临床应用[J]. 中国当代儿科杂志,2022,24(7):786-791.
[38].Ivy DD,Abman SH,Barst RJ,et al. Pediatric pulmonary hypertension[J]. J Am Coll Cardiol,2013,62(25 suppl):D117-D126.
[39].Mukherjee D,Konduri GG. Pediatric pulmonary hypertension:definitions,mechanisms,diagnosis,and treatment[J]. Compr Physiol,2021,11(3):2135-2190.

相似文献/References:

[1]朱鹏力 赵信科 蒋虎刚 李应东.心力衰竭合并中枢性睡眠呼吸暂停的治疗方案及机制研究新进展[J].心血管病学进展,2021,(1):59.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
　ZHU Pengli ZHAO XinkeJIANG HugangLI yingdong.Advances in Treatment of Heart Failure with Central Sleep Apnea and Its Pathologic Mechanism[J].Advances in Cardiovascular Diseases,2021,(12):59.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[2]张啸,刘剑刚,董国菊.射血分数保留性心力衰竭常见合并症的病理机制及治疗策略[J].心血管病学进展,2024,(2):125.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.007]
　ZHANG Xiao,LIU Jiangang.The Pathophysiology and Treatment Strategies of Comorbidities in HFpEF[J].Advances in Cardiovascular Diseases,2024,(12):125.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.007]

更新日期/Last Update: 2025-01-08